


INTENDED USE

ichroma™ HbA1c is a fluorescence Immunoassay (FIA) for the quantitative determination of HbA1c(Hemoglobin A1c) in human whole blood. It is useful as an aid in management and monitoring of the long-term glycemic status in patients with diabetes mellitus.

For *in vitro* diagnostic use only.

INTRODUCTION

Glycated protein is formed post-translationally through the slow, nonenzymatic reaction between glucose and amino groups on proteins. HbA1c is a clinically useful index of mean glycemia during the preceding 120 days, the average life span of erythrocytes. Carefully controlled studies have documented a close relationship between the concentrations of HbA1c and mean glycemia. HbA1c is considered as a more reliable parameter in monitoring glycemia over the glycemic reading with the conventional glucometer.

PRINCIPLE

The test uses a sandwich immunodetection method; the detector antibody in buffer binds to antigen in sample, forming antigen-antibody complexes, and migrates onto nitrocellulose matrix to be captured by the other immobilized-antibody on test strip.

The more antigen in sample forms the more antigen-antibody complex and leads to stronger intensity of fluorescence signal on detector antibody. Instrument for ichroma™ tests displays the content of glycated hemoglobin in terms of percent of the total hemoglobin in blood.

COMPONENTS

ichroma™ HbA1c consists of 'Cartridges', 'Detection Buffer Tubes', 'Hemolysis Buffer Vial' and an 'ID chip'.

- The cartridge contains a test strip, the membrane which has anti human HbA1c at the test line, while rabbit IgG at the control line.
- Each cartridge is individually sealed in an aluminum foil pouch containing a desiccant. 25 sealed cartridges are packed in a box which also contains an ID chip.
- The detection buffer contains anti human HbA1c-fluorescence conjugate, anti rabbit IgG-fluorescence conjugate, bovine serum albumin (BSA) as a stabilizer and sodium azide in phosphate buffered saline (PBS) as a preservative.
- The detection buffer is pre-dispensed in a separate tube. 25 detection buffer tubes are packaged in a box and further packed in a Styrofoam box with ice-pack for the shipment.
- The hemolysis Buffer contains nonionic detergent and sodium azide as preservative in PBS.

WARNINGS AND PRECAUTIONS

- For *in vitro* diagnostic use only.
- Carefully follow the instructions and procedures described in this 'Instruction for use'.
- Use only fresh samples and avoid direct sunlight.
- Lot numbers of all the test components (cartridge, ID chip and detection buffer) must match each other.
- Do not interchange the test components between different lots or use the test components after the

expiration date, either of which might yield misleading of test result(s).

- Do not reuse. A detection buffer tube should be used for processing one sample only. So should a cartridge.
- The cartridge should remain sealed in its original pouch before use. Do not use the cartridge, if is damaged or already opened.
- Frozen sample should be thawed only once. For shipping, samples must be packed in accordance with the regulations. HbA1c Sample with severe hemolytic and hyperlipidemia cannot be used and should be recollected.
- Just before use, allow the cartridge, detection buffer and sample to be at room temperature for approximately 30 minutes.
- ichroma™ HbA1c** as well as the instrument for ichroma™ tests should be used away from vibration and/or magnetic field. During normal usage, it can be noted that instrument for ichroma™ tests may produce minor vibration.
- Used detection buffer tubes, pipette tips and cartridges should be handled carefully and discarded by an appropriate method in accordance with relevant local regulations.
- The mixture of Detection Buffer and Hemolysis buffer must be used within 1 hour after mixing.
- The mixture of Detection Buffer and Hemolysis buffer must be used within 1 hour after mixing.
- An exposure to larger quantities of sodium azide may cause certain health issues like convulsions, low blood pressure and heart rate, loss of consciousness, lung injury and respiratory failure.
- ichroma™ HbA1c** will provide accurate and reliable results subject to the following conditions.
 - Use **ichroma™ HbA1c** should be used only in conjunction with instrument for ichroma™ tests.
 - Any anticoagulants other than EDTA, heparin sodium, sodium citrate should be avoided.

STORAGE AND STABILITY

- The cartridge is stable for 20 months (while sealed in an aluminum foil pouch) if stored at 4 - 30°C.
- The detection buffer pre-dispensed in a tube is stable for 20 months if stored at 2 - 8°C.
- The hemolysis buffer dispensed in a vial is stable for 20 months if stored at 4 - 30°C.
- After the cartridge pouch is opened, the test should be performed immediately.

LIMITATIONS OF THE TEST SYSTEM

- The test may yield false positive result(s) due to the cross-reactions and/or non-specific adhesion of certain sample components to the capture/detector antibodies.
- The test may yield false negative result. The non-responsiveness of the antigen to the antibodies is most common where the epitope is masked by some unknown components, so as not to be detected or captured by the antibodies. The instability or degradation of the antigen with time and/or temperature may cause the false negative as it makes antigen unrecognizable by the antibodies.
- Other factors may interfere with the test and cause erroneous results, such as technical/procedural errors, degradation of the test components/reagents or presence of interfering substances in the test samples.
- Any clinical diagnosis based on the test result must be supported by a comprehensive judgment of the concerned physician including clinical symptoms and other relevant test results.
- The test conditions for **ichroma™ HbA1c** are as follow.
 - Temperature : 20~30°C
 - Humidity : 10~70%

MATERIALS SUPPLIED

REF CFPC-38

Components of **ichroma™ HbA1c**

- Cartridge Box:
 - Cartridges 25
 - ID Chip 1
 - Instruction For Use 1
- Box containing Detection Buffer tubes
 - Detection Buffer Tubes 25
- Hemolysis Buffer Vial
 - Hemolysis Buffer Vial (3 mL) 1

MATERIALS REQUIRED BUT SUPPLIED ON DEMAND

Following items can be purchased separately from **ichroma™ HbA1c**.

Please contact our sales division for more information.

- Instrument for ichroma™ tests
 - ichroma™ Reader** **REF** FR203
 - ichroma™ D** **REF** 13303
- ichroma™ Printer** **REF** FPFR007
- ichroma™ HbA1c Control** **REF** CFPO-6
- 5 µL Capillary tube** **REF** CFPO-19

SAMPLE COLLECTION AND PROCESSING

The sample type for **ichroma™ HbA1c** is human whole blood.

- It is recommended to test the sample within 24 hours after collection.
- Samples may be stored for up to a week at 2-8°C prior to being tested.
- If testing will be delayed more than a week, samples should be frozen at -70°C or below. Samples stored frozen at -70°C or below for 3 months showed no performance difference.
- Once the sample was frozen, it should be used one time only for test, because repeated freezing and thawing can result in the change of test values.

INTERPRETATION OF TEST RESULT

- Instrument for ichroma™ tests calculates the test result automatically and displays HbA1c concentration of the test sample in terms of % (NGSP), mmol/mol (IFCC), mg/dL (eAG).
- The cut-off (reference range)
 - NGSP (%) : 4.5~6.5 %
 - IFCC (mmol/mol) : 26~48 mmol/mol
- Working range
 - NGSP (%) : 4~15 %
 - IFCC (mmol/mol) : 20.2~140.4 mmol/mol
 - eAG (mg/dL) : 68.1~383.8 mg/dL

QUALITY CONTROL


- Quality control tests are a part of the good testing practice to confirm the expected results and validity of the assay and should be performed at regular intervals.
- The control tests should be performed immediately after opening a new test lot to ensure the test performance is not altered.
- Quality control tests should also be performed whenever there is any question concerning the validity of the test results.
- Control materials are not provided with **ichroma™ HbA1c**. For more information regarding obtaining the control materials, contact **Boditech Med Inc.'s Sales Division for assistance**. (Please refer to the instruction for use of control material.)

PERFORMANCE CHARACTERISTICS

- Specificity:** There, in test samples, are biomolecules such as Gentisic acid (200mg/ml), Bilirubin (20mg/ml), Triglyceride (3000mg/dl), Ascorbic acid (5mg/dl) and Glucose (300mg/ml) in higher concentration than their normal physiological levels. But this doesn't interfere with the **ichroma™ HbA1c** test measurements, nor occurs any significant cross-reactivity.
- Precision:** The intra-assay precision was calculated by one evaluator, who tested different concentration of control standard ten times each with three different lots of **ichroma™ HbA1c**. The inter-assay precision was confirmed by 3 different evaluators with 3 different lots, testing ten times each different concentration.

HbA1c (%)	Intra-assay			Inter-assay		
	Mean	SD	CV(%)	Mean	SD	CV(%)
5.4	5.34	0.08	1.58	5.34	0.15	2.82
8.4	8.39	0.15	1.90	8.41	0.17	2.04

- Comparability:** HbA1c concentrations of 200 clinical samples were quantified independently with **ichroma™ HbA1c** and Roche Cobas integra800 as per prescribed test procedures. Test results were compared and their comparability was investigated with linear regression and coefficient of correlation (R). Linear regression and coefficient of correlation between the two tests were $Y=1.0025X - 0.2003$ and $R = 0.9855$ respectively.












**REFERENCES**

- Goldstein DE, Little RR, Lorenz RA, Malone JJ, Nathan D, Peterson CM. Tests of glycemia in diabetes. Diabetes Care 1995; 18:896-909.
- Bunn HF. Nonenzymatic glycosylation of protein: relevance to diabetes. Am J Med 1981; 70:325-30.
- Jovanovic L, Peterson CM. The clinical utility of glycosylated hemoglobin. Am J Med 1981; 70:331-8.
- Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310:341-6.
- Goldstein DE, Little RR, Wiedmeyer HM, England JD, McKenzie EM. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986; 32:B64-70.
- Goldstein DE, Little RR, England JD, Wiedemeyer H-M, McKenzie E. Methods of glycosylated hemoglobins: high performance liquid chromatography and thiobarbituric acid colorimetric methods. In: Clarke WL, Larner J, Pohl SL, eds. Methods in diabetes research, Vol. 2. New York: John Wiley, 1986:475-504.
- Tahara Y, Shima K. The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care 1993; 16:1313-4.
- Svendsen PA, Lauritzen T, Soegaard U, Nerup J. Glycosylated haemoglobin and steady-state mean blood glucose concentration in type 1 (insulin-dependent) diabetes. Diabetologia 1982; 23:403-5.
- Cefalu WT, Wang ZQ, Bell-Farrow A, Kiger FD, Izlar C. Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. Clin Chem 1994; 40:1317-21.
- Singer DE, Coley CM, Samet JH, Nathan DM. Tests of

glycemia in diabetes mellitus. Their use in establishing a diagnosis and in treatment. Ann Intern Med 1989; 110:125-37.

- Molnar GD. Clinical evaluation of metabolic control in diabetes. Diabetes 1978; 27:216-25.
- UK Prospective Diabetes Study. Reduction in HbA1c with basal insulin supplement, sulfonylurea or biguanide therapy in maturity-onset diabetes. Diabetes 1985; 34:793-8.
- Baker JR, Johnson RN, Scott DJ. Serum fructosamine concentrations in patients with type II (non-insulin-dependent) diabetes mellitus during changes in management. BMJ (Clin Res Ed) 1984; 288:1484-6.
- Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 1995; 18:440-7.
- Brooks DE, Devine DV, Harris PC, et al. RAMP(TM): A rapid, quantitative whole blood immunochromatographic platform for point of care testing. Clin Chem 1999; 45:1676-1678.

Note: Please refer to the table below to identify various symbols

	Read instructions for use
	Use by
	Batch code
	Catalog number
	Caution
	Manufacturer
	Authorized representative of the European Community
	In vitro diagnostic medical device
	Temperature limit
	Do not reuse
	This product fulfills the requirements of the Directive 98/79/EC on in vitro diagnostic medical devices

For technical assistance; please contact:

Boditech Med Inc.'s Technical Services

Tel: +82 33 243-1400

E-mail: sales@boditech.co.kr

Boditech Med Incorporated

43, Geodudanji 1-gil, Dongnae-myeon, Chuncheon-si, Gang-won-do 200-883 Republic of Korea

Tel: +(82) -33-243-1400

Fax: +(82) -33-243-9373

www.boditech.co.kr

EC REP Obelis s.a

Bd. Général Wahis 53,

1030 Brussels, BELGIUM

Tel: +(32) -2-732-59-54

Fax: +(32) -2-732-60-03

E-Mail: mail@obelis.net

